knowledge -WSS

knowledge

author：fashion 2025-09-30 00:40:16 - browse：8

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Cloning humans is technically possible. It's curious no one has tried

focus

WSS

Why palliative psychiatry is worth discussing

Community Health Systems hospitals under DOJ investigation

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

The Harvard botanist who searched for psychedelics in the Amazon

Community Health Systems hospitals under DOJ investigation

Antivenom research: Lessons from HIV applied in search for universal antidote

Wikipedia

knowledge

entertainment

Heart attack and stroke risk calculators need revising

The battle over the Brookhaven Landfill on Long Island

23andMe had bad news about my health. I wish a person had delivered it

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New documents shed light on MD Anderson Cancer Institute feud

Jerome Adams on the need for new antivirals for Covid

What would happen to your eyes if you looked at the solar eclipse?

Sports medicine is finally prioritizing gender equality

CDC concerned about possible undetected monkeypox spread in U.K.

focus

Donald Trump's relentless attacks on special counsel Jack Smith

Paxlovid study fails to answer questions over benefit for broader groups

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

NIH study of ME/CFS points to clear biological hallmarks

Paxlovid study fails to answer questions over benefit for broader groups

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

explore

focus

focus

explore